Company Profile. February 2018
|
|
- Dwayne Moody
- 5 years ago
- Views:
Transcription
1 Company Profile February 2018
2 We pioneer immunotherapy, to enable a world where cancer patients can defeat cancer on their own. From GreenPeptide to BrightPath on July 1,
3 Company Profile 2
4 BrightPath Biotherapeutics A clinical-stage biopharmaceutical company focused on immuno-oncology Our pipeline covers cancer peptide vaccine, cell therapy, and immuno-modulator antibodies to address the most exciting and fast growing I/O market Cell Therapy ips-t Peptide ITK-1 GRN-1201 GRN-1301 Neoantigen Fully-personalized neoantigen vaccine Antibody Immuno-modulator 3
5 Our Business Model We have established a systematic and consistent development process, from the basic research and preclinical studies to obtaining a POC, in cooperation with academia and our partner companies Basic Research Pre-Clinical Study Early-stage Clinical Study Late-stage Clinical Study Launch BP considers conduct of P3 study and sales of regenerative/cell medicine subject to accelerated approval in JP. Partnering / License-out Collaboration with Academia / Biotech Seeds Strong research skill and experience in our own research laboratory Strong development skills/know-how accumulated based on the development of ITK-1 in Japan/GRN-1201 in US : Partnering/License-out Timing: Partnering at earlier stage would be possible. 4
6 Our Advantage -Project Driving- BrightPath has expertise in drug project management from drug discovery through clinical supported by our experience in late-stage clinical trials Drug discovery Kawasaki Research Laboratories Functions Clinical Development Phase I-III Advanced Immuno Therapy Pre-clinical Regulatory Monitoring Data management GCP inspection Biostatics CMC Kurume(Testing Technology) Investigational drug management Licensing / M&A / Collaborative research Collaboration External company / academia (CRO/ CMO etc.) 5
7 Company Overview Capital JPY 3,774 million (as of March 2017) Management Team Chief Executive Officer Chief Operative Officer Chief Financial Officer Director External Director External Auditor Kenichi Nagai Yutaka Waki, D.V.M. Teruhiko Sakai, CPA Akira Yamada, Ph.D. Professor, Kurume University Hirotaka Takeuchi, Ph.D. Professor, Harvard Business School Honorary Professor, Hitotsubashi University Yoshihiro Imai Taketoshi Abe Yoshiyasu Yamaguchi Employees 40 (as of June 2017) 6
8 Company Overview Location Headquarters Fukuoka Bio Incubation Center, 1-1 Hyakunenkoen, Kurume-shi, Fukuoka Tokyo Branch Kojimachi Central Building 7F, Kojimachi, Chiyoda-ku, Tokyo Kawasaki Research Laboratory Life Innovation Center 412, Tonomachi, Kawasaki-ku, Kawasaki-shi, Kanagawa 7
9 Company History :Corporate history :Pipeline (May) Established at Fukuoka Prefecture as GreenPeptide (Oct.) Listed on the Tokyo stock exchange (code: 4594) (Oct.) Start of phase I clinical trials of GRN-1201 for malignant melanoma in the US (Jul.) GreenPeptide changed its name to BrightPath Biotherapeutics Co., Ltd. (Jan.) Start of phase II clinical trials of GRN-1201 in combination with an immune checkpoint antibody for non-small cell lung cancer in the US (Nov.) An exclusive license contract related to ITK-1 commenced with FUJIFILM Corporation (Jun.) Start of phase III clinical trials of ITK-1 in patients with castrationresistant prostate cancer (Aug.) Opened Kawasaki Research Laboratories at Kanagawa Prefecture 8
10 Research and Licensing Collaborations Partner Product Collaboration Territory Year Fujifilm ITK-1 Out-licensing WW 2011 Kanagawa Prefecture Cancer Center GRN-1301 In-licensing WW 2016 Kanagawa Prefecture Cancer Center Novel neoantigen Research Collaboration 2016 National Cancer Center Japan Personalized neoantigen vaccine Research Collaboration 2017 Kanagawa Prefecture Cancer Center / Tokyo university Personalized neoantigen vaccine Research Collaboration 2018 Mie University Personalized neoantigen vaccine Research Collaboration 2018 Advanced Immune Therapy (Originated from Tokyo University) ips-t In-licensing JP 2016 Juntendo University ips-t Research Collaboration
11 Kawasaki Research Laboratories (KRL) KRL in the Life Innovation Center in Kawasaki City is located across the Tama River from Tokyo International Airport (Haneda Airport) KRL focuses on the research of neoantigens and immuno-modulators Haneda Airport KRL 神奈川県川崎市川崎区殿町 3 丁目 25 番 22 ライフイノベーションセンター 412 電話 FAX
12 Financial Highlight Cash Balance JPY 3.9 billion (December 31, 2017) Achieved money raising (JPY3.2B) in January, 2018 No Debt Cash Expenditures JPY 2 billion (Forecast for FY 2017) Market Capitalization JPY 33.9 billion (January 31, 2017) TSE Mothers (Tokyo)
13 R&D Pipeline 12
14 Pipeline Project Indication Region Basic Research Preclinical Phase I II III Launch Partners ITK-1 Semi-personalized cancer peptide vaccine Prostate cancer JP FUJIFILM Corporation GRN-1201 NSCLC US Cancer peptide vaccine In combination with an immune checkpoint inhibitor (for NSCLC) Melanoma US Out-licensing Candidate GRN-1301 Neoantigen T790M point mutation antigen vaccine NSCLC TBD Out-licensing Candidate ips-t Induced pluripotent stem cell (ipsc) derived rejuvenated T cell therapy Lymphoma JP Joint development project with: University of Tokyo Juntendo University 13
15 ITK-1 Semi-personalized cancer peptide vaccine HLA-A24 restricted peptide (Common in Japanese patients) Out-licensed to FUJIFILM Corporation in 2011 A Phase III clinical study is ongoing in Japan (currently following-up) Indication : Castration-resistant prostate cancer Cell Therapy ips-t Peptide ITK-1 GRN-1201 GRN-1301 Neoantigen Fully-personalized neoantigen vaccine Antibody Immuno-modulator 14
16 ITK-1: Clinical Data The efficacy of ITK-1 was suggested by prior clinical studies and institutional clinical investigations Castration-resistant prostate cancer Overall Survival (OS) ITK-1 (Ph1+Extension study) n=15, Open label 23.8 *1 Historical Control ITK-1 (Kurume University) n=12, Open label Decetaxel (Ph3 TAX327) n=335, Approved in * *2 Mitoxantrone (Ph3 TAX327) n= * (Reference) *1 BrightPath Biotherapeutics/ *2 Noguchi M, et al. The Prostate 2011; 71: *3 Berthold DR, et al. J Clin Oncol 2008; 26: month Most of AEs are under CTCAE Grade 2 (Injection site reaction) 15
17 GRN-1201 Cancer peptide vaccine consisting of four peptide antigens HLA-A2 restricted peptide (Common in American and European patients) Clinical studies are ongoing in the US Phase 1 study for melanoma (n=18) Phase 2 study for NSCLC (Combination with immune checkpoint antibodies) Cell Therapy ips-t Peptide ITK-1 GRN-1201 GRN-1301 Neoantigen Fully-personalized neoantigen vaccine Antibody Immuno-modulator 16
18 GRN-1201: Antigen Expression GRN-1201 targeting TAAs are expressed in many types of cancer Melanoma: >85% NSCLC: >95% Majority of tumor samples expressed all four target TAAs MELANOMA NSCLC Adeno Ca CRC PROSTATE Adeno Ca OVARIAN All types PANCREAS Adeno Ca SCCHN Case Number % 31/ % 74/ % 93/ % 28/ % 83/ % 26/ % 76/ % BrightPath Biotherapeutics, In-house data More than 1,000 patients have been administered with GRN-1201 homologue/related peptide in institutional clinical investigations at Kurume University Highly favorable immunogenicity and safety profiles 17
19 GRN-1201: Pharmacology GRN-1201 peptides demonstrated capability of inducing immune response Induction of immune responses by each GRN 1201 homologous peptide in HLA A*02+ Japanese patients with advanced cancer (Data from institutional clinical investigations at Kurume University) CTL IgG CTL & IgG DTH* Peptide Total A2+ pts Pts analyzed Pts induced % Pts analyzed Pts induced % Pts analyzed Pts induced % Pts analyzed Pts induced % A % % % % B % % % % C % % % % D % % % % *DTH: Delayed-type hypersensitivity BrightPath Biotherapeutics In-house data 18
20 GRN-1301 Cancer peptide vaccine targeting a drug-resistance-derived gene mutation (EGFR T790M point mutation) caused by primary treatment for NSCLC with EGFR-TKI HLA-A2 restricted peptide (Common in American and European patients) Confirmed healthy donors and EGFR-TKI treated patients immunogenic response to the candidate peptide Basic research Indication:Non-small cell lung cancer(nsclc) Cell Therapy ips-t Peptide ITK-1 GRN-1201 GRN-1301 Neoantigen Fully-personalized neoantigen vaccine Antibody Immuno-modulator 19
21 GRN-1301: Background Cancer immunotherapy for a drug-resistant gene mutation (EGFR T790M point mutation) involved in resistance to a primary treatment for lung cancer, EGFR-TKI Annual number of newly diagnosed patients: 500,000 patients Approximately 80% of these had NSCLC (United States: 210,000 patients, EU (Top 5 countries): 200,000 patients, Japan: 100,000 patients) 1 Primary EGFR mutation rate 10-15% T790M mutation (secondary EGFR mutation) rate in EGFR-TKI-resistant patients EGFR tyrosine kinase inhibitors (EGFR-TKI) 2 are used as standard therapy 60% 1 Source: GLOBOCAN Tarceva (erlotinib, sales amount in 2015: $1.59 bn), Iressa (gefitinib), and Giotrif (afatinib) were approved by 3 bureaus. 20
22 GRN-1301: Background Neoantigen T790M gene mutation is a therapeutic target for cancer immunotherapy Immunogenicity of antigen epitope (peptide) has been demonstrated A patent was granted in the US Only appear in cancer cells Escape (antigen loss) from immune surveillance mechanisms may not occur Driver mutations are essential for cancer malignancy, occuring against a challenge by EGFR-TKI (primary treatment) Relatively high incidence 21
23 ips-t Induced pluripotent stem cell (ipsc) derived rejuvenated T cell therapy The world s first clinical application of rejuvenated medicine in cancer immunotherapy Joint development project with the Institute of Medical Science of University of Tokyo and Juntendo University Indication: Lymphoma Cell Therapy ips-t Peptide ITK-1 GRN-1201 GRN-1301 Neoantigen Fully-personalized neoantigen vaccine Antibody Immuno-modulator 22
24 ips-t For T cell therapy, securing the sufficient number of T cells with anti-cancer activity has been challenging. Through the use of ips technology, an unlimited number of rejuvenated (high-activity) T cells can be supplied 23
25 Fully-personalized Cancer Neoantigen Vaccine A neoantigen is defined as a tumor antigen generated from gene mutations present in cancer cells. The human immune system recognizes neoantigens as non-self, which induce immune responses. Since tumor neoantigens are unique to each patient s tumor, they are considered as ideal targets of personalized treatment BrightPath is conducting collaborative researches to develop a methodology of fullypersonalized cancer neoantigen vaccine with Japanese academia Cell Therapy ips-t Peptide ITK-1 GRN-1201 GRN-1301 Neoantigen Fully-personalized neoantigen vaccine Antibody Immuno-modulator 24
26 Fully-personalized Cancer Neoantigen Vaccine Development of Fully-personalized Cancer Neoantigen Vaccine Cancer Patient Mutation Identification Vaccine Design Fullypersonalized Vaccine Tissues Biopsy NGS MS analysis Computing Modalities Peptide RNA/DNA Adjuvants Formulation 25
27 Fully-personalized Cancer Neoantigen Vaccine Research collaborations with Japanese leading academia/institute realize fullypersonalized cancer neoantigen vaccine therapy 26
28 We pioneer immunotherapy, to enable a world where cancer patients can defeat cancer on their own.
Pioneering vaccines that transform lives.
Pioneering vaccines that transform lives. Immunomic Therapeutics, Inc. LAMP-Vax for General Oncology Presentation Outline 1. Immunomic Therapeutics: corporate overview 2. Unmet need in cancer immunotherapy
More informationCorporate Presentation October 2018 Nasdaq: ADXS
Innovations in Immuno-Oncology Corporate Presentation October 2018 Nasdaq: ADXS Forward-Looking Statements This presentation contains forward-looking statements, including, but not limited to, statements
More informationCorporate Presentation September Nasdaq: ADXS
Corporate Presentation September 2018 Nasdaq: ADXS Forward-Looking Statements This presentation contains forward-looking statements, including, but not limited to, statements regarding the ability and
More informationInducing Tumor-Specific Ischemic Necrosis to Enhance the Efficacy of Checkpoint Inhibitors and Chemotherapy
Inducing Tumor-Specific Ischemic Necrosis to Enhance the Efficacy of Checkpoint Inhibitors and Chemotherapy Company Overview, September 2018 Safe Harbor Statement This presentation contains forward-looking
More informationDawson James Conference
Dawson James Conference October 2018 Forward-looking Statements Except for historical information, this presentation contains forward-looking statements, which reflect IMV s current expectations regarding
More informationREFERENCE CODE GDHC198DFR PUBLICAT ION DATE JUNE 2013 TARCEVA (NON-SMALL CELL LUNG CANCER) FORECAST AND MARKET ANALYSIS TO 2022
REFERENCE CODE GDHC198DFR PUBLICAT ION DATE JUNE 2013 TARCEVA (NON-SMALL CELL LUNG CANCER) Executive Summary Tarceva (erlotinib): Key Metrics in NSCLC Markets 2012 Tarceva Sales US 5EU Japan China India
More informationDS-8201 Strategic Collaboration
DS-8201 Strategic Collaboration DAIICHI SANKYO CO., LTD George Nakayama Chairman and CEO March 29, 2019 Forward-Looking Statements Management strategies and plans, financial forecasts, future projections
More informationIMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics
IMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics Oncology Autoimmune Diseases Rodman & Renshaw 19 th Annual Global Investment Conference Michael R. Garone, Principal Executive Officer and CFO Forward-Looking
More informationImmunocore and MedImmune announce new collaboration to conduct immuno-oncology combination trials in melanoma
PRESS RELEASE IMMUNOCORE LIMITED Immunocore and MedImmune announce new collaboration to conduct immuno-oncology combination trials in melanoma (Oxford, UK, 16 April 2015) Immunocore Limited, a world-leading
More informationREFERENCE CODE GDHC200DFR PUBLICAT ION DATE JUNE 2013 AVASTIN (NON-SMALL CELL LUNG CANCER) FORECAST AND MARKET ANALYSIS TO 2022
REFERENCE CODE GDHC200DFR PUBLICAT ION DATE JUNE 2013 AVASTIN (NON-SMALL CELL LUNG CANCER) AVASTIN (NON-SMALL CELL LUNG CANCER) - Executive Summary Avastin (bevacizumab): Key Metrics in NSCLC Markets 2012
More informationMOLOGEN AG. Our research for you. Annual Results Analysts Call March 21, 2013
Our research for you. Annual Results 2012 Analysts Call March 21, 2013 Disclaimer Certain statements in this communication contain formulations or terms referring to the future or future developments,
More informationDynavax Corporate Presentation
Dynavax Corporate Presentation Forward-Looking Statements This presentation contains forward-looking statements, including statements regarding our HEPLISAV-B TM regulatory submissions, product profile,
More informationCORPORATE PRESENTATION
CORPORATE PRESENTATION June 2017 FORWARD LOOKING SAFE HARBOR STATEMENT This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.
More informationSavolitinib Global Phase II Trial Initiated in EGFR Mutant Non-Small Cell Lung Cancer
Savolitinib Global Phase II Trial Initiated in EGFR Mutant Non-Small Cell Lung Cancer Initiation of expanded Phase II trials in NSCLC triggers US$10 million milestone from AstraZeneca to Chi-Med New study
More informationREFERENCE CODE GDHC196DFR PUBLICAT ION DATE JUNE 2013 ABRAXANE (NON-SMALL CELL LUNG CANCER) FORECAST AND MARKET ANALYSIS TO 2022
REFERENCE CODE GDHC196DFR PUBLICAT ION DATE JUNE 2013 ABRAXANE (NON-SMALL CELL LUNG CANCER) Executive Summary Abraxane (nab-paclitaxel): Key Metrics in NSCLC Markets 2012 Abraxane Sales US 5EU $98.34m
More informationPioneering vaccines that transform lives.
Pioneering vaccines that transform lives. Immunomic Therapeutics, Inc. LAMP-Vax for Glioblastoma: CMV-LAMP-Vax Executive Summary Executive Summary pp65-lamp-vax First Line Therapy for Glioblastoma Multiforme
More information33 rd Annual J.P. Morgan Healthcare Conference. January 2015
33 rd Annual J.P. Morgan Healthcare Conference January 2015 Forward-looking Statements This presentation contains forward-looking statements, which express the current beliefs and expectations of management.
More informationCorporate Presentation March 2016
Corporate Presentation March 2016 Forward Looking Safe Harbor Statement This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.
More informationValneva Reports Strong 2017 Revenues Driven by Double Digit Product Sales Growth
Valneva Reports Strong 2017 Revenues Driven by Double Digit Product Sales Growth Strong sales performance in 2017 (unaudited) Total revenues of 109.8 million in 2017 (2016-97.9 million) representing year-on-year
More informationREFERENCE CODE GDHC207DFR PUBLICAT ION DATE JUNE 2013 GILOTRIF (NON-SMALL CELL LUNG CANCER) FORECAST AND MARKET ANALYSIS TO 2022
REFERENCE CODE GDHC207DFR PUBLICAT ION DATE JUNE 2013 GILOTRIF (NON-SMALL CELL LUNG CANCER) GILOTRIF (NON-SMALL CELL LUNG CANCER) - Executive Summary Gilotrif: Key Metrics in NSCLC Markets 2022 Gilotrif
More informationVeriStrat Poor Patients Show Encouraging Overall Survival and Progression Free Survival Signal; Confirmatory Phase 2 Study Planned by Year-End
AVEO and Biodesix Announce Exploratory Analysis of VeriStrat-Selected Patients with Non-Small Cell Lung Cancer in Phase 2 Study of Ficlatuzumab Presented at ESMO 2014 Congress VeriStrat Poor Patients Show
More informationFY2007 Consolidated Financial Overview
FY2007 Consolidated Financial Overview CHUGAI PHARMACEUTICAL CO., LTD. Executive Vice President and CFO Ryuzo Kodama January 30/31, 2008 Forward-Looking Statements This presentation may include forward-looking
More informationIMMUNOMEDICS, INC. November Advanced Antibody-Based Therapeutics. Oncology Autoimmune Diseases
IMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics Oncology Autoimmune Diseases November 2017 Forward-Looking Statements This presentation, in addition to historical information, contains certain
More informationNEWSLETTER June Summer greetings from Follicum
NEWSLETTER June 2018 Follicum hopes that this newsletter reaches as many of the company's owners and stakeholders as possible. If you wish to follow our continued development, please register your e-mail
More informationMHC Tetramers and Monomers for Immuno-Oncology and Autoimmunity Drug Discovery
MHC Tetramers and Monomers for Immuno-Oncology and Autoimmunity Drug Discovery Your Partner in Drug Discovery and Research MHC Tetramer Background T-Cell Receptors recognize and bind to complexes composed
More informationAsterias Biotherapeutics NYSE American: AST
Clinical-Stage Cell Therapy Programs Addressing Significant Unmet Medical Needs in Neurology and Oncology Asterias Biotherapeutics NYSE American: AST November 2017 Forward-Looking Statements Statements
More informationREFERENCE CODE GDHC199DFR PUBLICAT ION DATE JUNE 2013 XALKORI (NON-SMALL CELL LUNG CANCER) FORECAST AND MARKET ANALYSIS TO 2022
REFERENCE CODE GDHC199DFR PUBLICAT ION DATE JUNE 2013 XALKORI (NON-SMALL CELL LUNG CANCER) Executive Summary Xalkori (crizotinib): Key Metrics in NSCLC Markets 2012 Xalkori Sales US 5EU Japan China India
More informationArming the patient s immune system to fight cancer
Arming the patient s immune system to fight cancer Redeye - Fight Cancer Seminar 10 th March 2017 Øystein Soug, CEO Important notice and disclaimer This report contains certain forward-looking statements
More informationJune IMMUNE DESIGN The in vivo generation of cytotoxic CD8 T cells (CTLs)
June 2015 IMMUNE DESIGN The in vivo generation of cytotoxic CD8 T cells (CTLs) 1 Forward-looking Statements This presentation contains forward-looking statements with respect to, among other things, our
More informationClovis Oncology Announces Q Operating Results and Corporate Update. November 3, :05 PM ET
Clovis Oncology Announces Q3 2016 Operating Results and Corporate Update November 3, 2016 4:05 PM ET Rucaparib New Drug Application (NDA) accepted for Priority Review in the treatment of advanced BRCA-mutant
More informationCompany overview. Highlights for the 1 st quarter 2018 (January-March)
Company overview Vaccibody is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies. The company is a leader in the rapidly developing field of
More informationAVEO Oncology Announces Strategic Restructuring. AVEO to Host Conference Call Wednesday, June 5 at 8:30 a.m. ET
NEWS RELEASE FOR IMMEDIATE RELEASE AVEO Oncology Announces Strategic Restructuring AVEO to Host Conference Call Wednesday, June 5 at 8:30 a.m. ET CAMBRIDGE, Mass., June 4, 2013 AVEO Oncology (NASDAQ: AVEO)
More information3Q 2016 presentation
Arming the patient s immune system to fight cancer 3Q 2016 presentation 17 November 2016 Important notice and disclaimer This report contains certain forward-looking statements based on uncertainty, since
More informationCAELUM BIOSCIENCES. Corporate Overview May, 2017
CAELUM BIOSCIENCES Corporate Overview May, 2017 Forward Looking Statements Statements in this presentation that are not descriptions of historical facts are forward looking statements within the meaning
More informationSumitomo Dainippon Pharma to Acquire Tolero Pharmaceuticals, Inc. (US Biotechnology Company)
December 21, 2016 Sumitomo Dainippon Pharma Co., Ltd. Sumitomo Dainippon Pharma to Acquire Tolero Pharmaceuticals, Inc. (US Biotechnology Company) Sumitomo Dainippon Pharma Co., Ltd. (Head office: Osaka,
More informationGene Techno Science Co., Ltd.
Gene Techno Science Co., Ltd. Execution of Share Exchange Agreement and Conversion of Advanced Cell Technology and Engineering into Wholly- Owned Subsidiary of Gene Techno Science January 17 th, 2019 Cautionary
More informationInfinity Highlights Promising Preclinical Hedgehog Data and Announces First Quarter Financial Results
Infinity Highlights Promising Preclinical Hedgehog Data and Announces First Quarter Financial Results Heat Shock Protein 90 Program Continues to Advance Toward Potential Registration Trial CAMBRIDGE, Mass.,
More informationNASDAQ: PBMD, ASX: PRR
NASDAQ: PBMD, ASX: PRR Notice: Forward Looking Statements The purpose of the presentation is to provide an update of the business of Prima BioMed Ltd ACN 009 237 889 (ASX:PRR; NASDAQ:PBMD). These slides
More informationNational Bank 8th Annual Quebec Conference TSX: IMV. May 30, IMV Inc. All rights reserved.
National Bank 8th Annual Quebec Conference TSX: IMV May 30, 2018 Forward-looking Statements Except for historical information, this presentation contains forward-looking statements, which reflect IMV Inc.
More informationAstraZeneca enhances long-term growth through Oncology investment in Acerta Pharma
AstraZeneca enhances long-term growth through Oncology investment in Acerta Pharma PUBLISHED17 December 2015Transaction includes late-stage, potential best-in-class irreversible small molecule BTK inhibitor,
More informationOncology Drug Development
Oncology Drug Development Presentation to BioShares Biotech Summit 2018 Queenstown, NZ 27 July 2018 ASX: KZA NASDAQ: KZIA Twitter: @KaziaTx Oncology remains the largest and fastest-growing sector of the
More informationAnti-epilepsy Drug VIMPAT for I.V. infusion 200mg Launched in Japan
Press Release March 25, 2019 UCB Japan Co., Ltd. Daiichi Sankyo Company, Limited Anti-epilepsy Drug VIMPAT for I.V. infusion 200mg Launched in Japan UCB Japan Co., Ltd. (headquarters: Shinjuku-ku, Tokyo;
More informationNovogen Limited. An emerging oncology drug developer with two clinical-stage programs NRT NVGN. April 2017
Novogen Limited An emerging oncology drug developer with two clinical-stage programs NRT April 2017 NVGN Forward-Looking Statements This presentation contains forward-looking statements within the meaning
More informationCOMPANY OVERVIEW. June CytomX Therapeutics, Inc.
COMPANY OVERVIEW June 2016 2016 CytomX Therapeutics, Inc. Forward Looking Statements Special Note Regarding Forward-Looking Statements This presentation may contain projections and other forward-looking
More informationCompany presentation. Claudio Bordignon, Chairman and CEO. Jefferies Global Healthcare Conference New York, 7 June 2012
Company presentation Claudio Bordignon, Chairman and CEO Jefferies Global Healthcare Conference New York, 7 June 2012 Forward-looking statements The presentation contains certain forward-looking statements.
More informationDetermined to realize a future in which people with cancer live longer and better than ever before
Determined to realize a future in which people with cancer live longer and better than ever before 3Q 2018 EARNINGS PRESENTATION NOVEMBER 2018 1 Forward-looking statements disclosure This presentation
More informationBank of America Merrill Lynch 2016 Health Care Conference
Bank of America Merrill Lynch 2016 Health Care Conference Dr. Steven Stein Chief Medical Officer David Gryska Chief Financial Officer May 11, 2016 Forward Looking Statements Except for the historical information
More informationGlobal Strategic Partners Merck and Pfizer Finalize Agreement to Co-Promote XALKORI (crizotinib)
Merck Media: Markus Talanow +49 6151 72 7144 Investor Relations: +49 6151 72 3321 Pfizer Media: Sally Beatty +1 212 733 6566 Investor Relations: Ryan Crowe +1 212 733 8160 News Release April 7, 2015 Not
More informationArming the patient s immune system to fight cancer. Q presentation
Arming the patient s immune system to fight cancer Q1 2017 presentation April 25 th 2017 Important notice and disclaimer This report contains certain forward-looking statements based on uncertainty, since
More informationOncology Therapeutics without Compromise APRIL 2011
Oncology Therapeutics without Compromise APRIL 2011 Forward Looking Statements This presentation contains forward-looking statements that involve substantial risks and uncertainties, including among other
More informationPPD S EXPERT HEMATOLOGY AND ONCOLOGY TEAM
HEMATOLOGY ONCOLOGY PPD S EXPERT HEMATOLOGY AND ONCOLOGY TEAM COMMITTED TO ADVANCING DRUG DEVELOPMENT IN ONCOLOGY $ MARKETPLACE COMPLEXITIES increasingly competitive marketplace and rising cost pressures
More informationCorporate Presentation May Transforming Immuno-Oncology Using Next-Generation Immune Cell Engagers
Corporate Presentation May 2016 Transforming Immuno-Oncology Using Next-Generation Immune Cell Engagers Forward-looking statements / safe harbor This presentation and the accompanying oral commentary contain
More informationNational Horizon Scanning Centre. Erlotinib (Tarceva) in combination with bevacizumab for advanced or metastatic non-small cell lung cancer
Erlotinib (Tarceva) in combination with bevacizumab for advanced or metastatic non-small cell lung cancer This technology summary is based on information available at the time of research and a limited
More informationNewLink Genetics Corporation Provides Operational Update and Reports Second Quarter 2015 Financial Results
July 31, 2015 NewLink Genetics Corporation Provides Operational Update and Reports Second Quarter 2015 Financial Results -Management to Host Conference Call Today at 8:30 a.m. ET- AMES, Iowa, July 31,
More informationLION. Corporate Presentation June 2016 BIOTECHNOLOGIES. Leadership & Innovation in Oncology
LION BIOTECHNOLOGIES Leadership & Innovation in Oncology Corporate Presentation June 2016 Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private
More informationTARGET A BETTER NOW FORWARD-LOOKING STATEMENTS NASDAQ: IMGN. Current as of January 2018
NASDAQ: IMGN TARGET A BETTER NOW Current as of January 2018 FORWARD-LOOKING STATEMENTS This presentation includes forward looking statements based on management's current expectations. These statements
More informationMelanoma Research Alliance-Pfizer Academic-Industry Partnership Awards
Melanoma Research Alliance-Pfizer Academic-Industry Partnership Awards Wendy K.D. Selig, President & CEO, MRA Julia Perkins, M.D. Medical Director, Oncology, Pfizer Melanoma Research Alliance Mission:
More informationThe Future of Allergy Treatment Ultra-Fast Allergy Immunotherapy
The Future of Allergy Treatment Ultra-Fast Allergy Immunotherapy 1 Anergis Focus on Allergy Immunotherapy (AIT) High Medical Need and Patient Demand 500 M allergic patients - fastest growing chronic condition
More informationPCI Biotech press release 24 th August Attachment
PCI Biotech press release 24 th August 2018 Attachment 1 BILE DUCT CANCER CLINICAL PHASE I STUDY Cohort IV is selected dose for pivotal study limited but promising data (per Aug 2018) Parameters 1) Average
More informationTissue or Liquid Biopsy? ~For Diagnosis, Monitoring and Early detection of Resistance~
16 th Dec. 2016. ESMO Preceptorship Program Non-Small-Cell Lung Cancer @Singapore Tissue or Liquid Biopsy? ~For Diagnosis, Monitoring and Early detection of Resistance~ Research Institute for Disease of
More informationImmuno-Oncology Clinical Trials Update: Checkpoint Inhibitors Others (not Anti-PD-L1/PD-1) Issue 4 January 2017
Delivering a Competitive Intelligence Advantage Immuno-Oncology Clinical Trials Update: Checkpoint Inhibitors Others (not Anti-PD-L1/PD-1) Issue 4 January 2017 Immuno-Oncology CLINICAL TRIALS UPDATE The
More informationHelix BioPharma Corporation
Helix BioPharma Corporation Tumor Defence Breaker Corporate Presentation National Investment Banking Association October 2016 Forward-looking Statements This presentation document contains certain forward-looking
More information4 th Quarter 2017 Earnings Review & Investor Update
4 th Quarter 2017 Earnings Review & Investor Update February 5, 2018 1 Forward-Looking Information This presentation contains statements about the Company s future plans and prospects that constitute forward-looking
More informationSpectrum Pharmaceuticals
Spectrum Pharmaceuticals Joe Turgeon President and CEO June 2018 Investor Presentation 1 Safe Harbor Statement This presentation contains forward looking statements regarding future events and the future
More informationFor personal use only
Prima BioMed Annual General Meeting CEO Presentation November 25, 2016 ASX:PRR; NASDAQ:PBMD Marc Voigt 1 Notice: Forward Looking Statements The purpose of the presentation is to provide an update of the
More informationThe Value of Product Development Partnerships in Vaccine Innovation. Hansi J. Dean International AIDS Vaccine Initiative
The Value of Product Development Partnerships in Vaccine Innovation Hansi J. Dean International AIDS Vaccine Initiative The Product Development Partnership Model A non-profit partnership of public and
More information37 th ANNUAL JP MORGAN HEALTHCARE CONFERENCE
37 th ANNUAL JP MORGAN HEALTHCARE CONFERENCE January 2019 Safe Harbor Statement This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as
More informationPledPharma. Redeye Life Science Seminar November 24, Nicklas Westerholm, CEO
PledPharma Redeye Life Science Seminar November 24, 2017 Nicklas Westerholm, CEO CEO & President Nicklas Westerholm PledPharma CMO Stefan Carlsson VP Product Strategy and Development Christian Sonesson
More informationLiquid Biopsies. Next Generation Cancer Molecular Diagnostics
Liquid Biopsies Next Generation Cancer Molecular Diagnostics Forward Looking Statements 2 Statements pertaining to future financial and/or operating results, future research, diagnostic tests and technology
More informationTaiwan s Premier Biopharma and the future leader in Immuno-Oncology
1 Taiwan s Premier Biopharma and the future leader in Immuno-Oncology Safe Harbor Statement This presentation contains certain forwardlooking statements. These forward-looking statements may be identified
More informationIntercell and Novartis form world leading strategic partnership to drive vaccines innovation
Intercell and Novartis form world leading strategic partnership to drive vaccines innovation Alliance creates opportunity for two strong innovators to combine development efforts in attractive areas Intercell
More informationPositioned for Growth
Positioned for Growth Annual Shareholders Meeting July 21, 2016 Paris Panayiotopoulos President and Chief Executive Officer David Sachs Non small cell lung cancer ARIAD clinical trial patient This presentation
More informationCorporate Presentation: Jefferies Global Healthcare Conference June 7, 2018
Corporate Presentation: Jefferies Global Healthcare Conference June 7, 2018 2018 CytomX Therapeutics, Inc. 1 Forward Looking Statements Special Note Regarding Forward-Looking Statements This presentation
More informationEarly drug development and emerging new treatments Unmasking Side Effects from First-in-Man Antineoplastic Medicine
Early drug development and emerging new treatments Unmasking Side Effects from First-in-Man Antineoplastic Medicine Ulrik Lassen, Professor, MD, PH.D. Phase 1 Unit, www.rigshospitalet.dk/phase1 Department
More informationMedia Release. Basel, 07 December 2017
Media Release Basel, 07 December 2017 Phase III IMpower150 study showed Tecentriq (atezolizumab) and Avastin (bevacizumab) plus chemotherapy reduced the risk of disease worsening or death by 38 percent
More informationEmisphere Technologies, Inc. Announces 2008 Second Quarter Financial Results
August 11, 2008 Emisphere Technologies, Inc. Announces 2008 Second Quarter Financial Results Conference Call/Webcast to be Held Monday, August 11 at 10:00 AM EDT CEDAR KNOLLS, N.J., Aug 11, 2008 /PRNewswire-FirstCall
More informationMore cancer patients are being treated with immunotherapy, but
Bristol-Myers Squibb and Five Prime Present Phase 1a/1b Data Evaluating Cabiralizumab (anti-csf-1 receptor antibody) with Opdivo (nivolumab) in Patients with Advanced Solid Tumors PRINCETON, N.J. & SOUTH
More informationJefferies 2016 Healthcare Conference. Reid Huber, PhD Chief Scientific Officer
Jefferies 2016 Healthcare Conference Reid Huber, PhD Chief Scientific Officer June 8, 2016 Forward-looking Statements Except for the historical information set forth herein, the matters set forth in this
More informationHALOZYME REPORTS SECOND QUARTER 2018 RESULTS
Contacts: Robert H. Uhl Managing Director Westwicke Partners, LLC 858-356-5932 robert.uhl@westwicke.com Laurie Stelzer 858-704-8222 ir@halozyme.com FOR IMMEDIATE RELEASE HALOZYME REPORTS SECOND QUARTER
More informationOur research for you. German Equity Forum November 2011
Our research for you. German Equity Forum 21-23 November 2011 Disclaimer Certain statements in this communication contain formulations or terms referring to the future or future developments, as well as
More informationDainippon Sumitomo Pharma
Progressing Towards an Internationally Competitive R&D-Oriented Pharmaceutical Company Dainippon Sumitomo Pharma Masayo Tada President and CEO 29th Annual J.P. Morgan Healthcare Conference January 11,
More informationCalliditas Therapeutics Q2 Report Webcast August 16, 2018, 10:00 Presenters: Renée Aguiar-Lucander, CEO Fredrik Johansson, CFO
Calliditas Therapeutics Q2 Report 2018 Webcast August 16, 2018, 10:00 Presenters: Renée Aguiar-Lucander, CEO Fredrik Johansson, CFO Disclaimer Important information This presentation may contain certain
More informationNASDAQ & TSX: IMV. BIO Investor Forum. October IMV Inc. All rights reserved.
NASDAQ & TSX: IMV BIO Investor Forum October 2018 Forward-looking Statements Except for historical information, this presentation contains forward-looking statements, which reflect IMV s current expectations
More informationNewLink Genetics Corporation
Cantor Fitzgerald Global Healthcare Conference NewLink Genetics Corporation NASDAQ: NLNK September 25, 2017 Forward-Looking Disclaimer This presentation contains forward-looking statements of NewLink that
More informationDISCOVERING AND DEVELOPING NEW IMMUNE ACTIVATING MECHANISMS AND ANTIBODIES TO IMPROVE CANCER SURVIVAL
DISCOVERING AND DEVELOPING NEW IMMUNE ACTIVATING MECHANISMS AND ANTIBODIES TO IMPROVE CANCER SURVIVAL Annual General Meeting 24 April 2018 Björn Frendéus, Acting CEO & CSO 1 IMMUNOTHERAPY HAS TRANSFORMED
More informationCorporate Overview. February 2018 NASDAQ: CYTR
Corporate Overview February 2018 NASDAQ: CYTR CytRx Safe Harbor Statement THIS PRESENTATION CONTAINS FORWARD-LOOKING STATEMENTS THAT INVOLVE CERTAIN RISKS AND UNCERTAINTIES. ACTUAL RESULTS COULD DIFFER
More informationONCOSEC ARMING THE IMMUNE SYSTEM TO FIGHT CANCER NASDAQ: ONCS
ONCOSEC TM ARMING THE IMMUNE SYSTEM TO FIGHT CANCER NASDAQ: ONCS 0 Forward Looking Statements Our commentary and responses to your questions may contain forward looking statements, as described in the
More informationBAVARIAN NORDIC BIO DEUTSCHLAND PRESENTATION OCTOBER 2014 CSE/OMX:BAVA, OTC:BVNRY
BAVARIAN NORDIC BIO DEUTSCHLAND PRESENTATION OCTOBER 2014 CSE/OMX:BAVA, OTC:BVNRY This presentation includes "forward-looking statements" that involve risks, uncertainties and other factors, many of which
More informationSlide 1. Investor presentation. London 5 February 2019
Slide Investor presentation London 5 February 209 Slide 2 Forward-looking statements Novo Nordisk s reports filed with or furnished to the US Securities and Exchange Commission (SEC), including this presentation
More informationCorporate Presentation
Corporate Presentation October 2017 Forward-looking Statements Except for historical information, this presentation contains forward-looking statements, which reflect Immunovaccine s current expectations
More informationINTERIM RESULTS AS OF JUNE 30, 2014 CSE/OMX:BAVA, OTC:BVNRY
INTERIM RESULTS AS OF JUNE 30, 2014 Q2 AUGUST 28, 2014 CSE/OMX:BAVA, OTC:BVNRY FINANCIAL HIGHLIGHTS 2.6 million doses IMVAMUNE delivered to the SNS during H1 (0.9 million in Q2) Increased contribution
More informationCorporate Presentation January 2019
Corporate Presentation January 2019 1 Forward-Looking Statement Disclosure Any statements made in this presentation relating to future financial or business performance, conditions, plans, prospects, trends,
More informationINTERIM RESULTS AS OF JUNE 30, 2017
INTERIM RESULTS AS OF JUNE 30, 2017 1 FORWARD-LOOKING STATEMENTS This presentation includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of
More informationVAL-083: Validated DNA-targeting Agent for Underserved Cancer Patients. September 2018
VAL-083: Validated DNA-targeting Agent for Underserved Cancer Patients September 2018 Forward-Looking Statements Any statements contained in this presentation that do not describe historical facts may
More informationAviragen Therapeutics, Inc. and Vaxart Inc. Joint Conference Call UNLOCKING THE FULL POTENTIAL OF ORAL VACCINES
Aviragen Therapeutics, Inc. and Vaxart Inc. Joint Conference Call UNLOCKING THE FULL POTENTIAL OF ORAL VACCINES October 30, 2017 Safe Harbor This presentation contains forward-looking statements about
More informationINTERIM MANAGEMENT STATEMENT Q3 2017
INTERIM MANAGEMENT STATEMENT Q3 2017 Significant progress across all clinical programs New pre-clinical immunooncology data to be presented during R&D Day in New York Research & Development highlights:
More informationJuly, ArQule, Inc.
July, 2012 Safe Harbor This presentation and other statements by ArQule may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to clinical
More informationCTA Strengths. Organisational Structure Board. CTA Board CEO. Background to Cancer Trials Australia What we do well An increasing struggle Conclusions
Models for Clinical Research: Cancer Trials Australia Professor Mark Rosenthal Chairman; Cancer Trials Australia and Director of Medical Oncology, Royal Melbourne Hospital For discussion: Background to
More informationImmune Checkpoint Inhibitors: The New Breakout Stars in Cancer Treatment
Immune Checkpoint Inhibitors: The New Breakout Stars in Cancer Treatment 1 Introductions Peter Langecker, MD, PhD Executive Medical Director, Global Oncology Clinipace Worldwide Mark Shapiro Vice President
More information